| Bepreve (U.S.N.L.M.) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dosing | 1 drop bid | ||||||||
| Chem Specs | bepotastine besilate 1.5% | ||||||||
| Quantities | 10ml | ||||||||
| Cost | 246.00/10ml | ||||||||
| Class | H1 receptor antagonist | ||||||||
| Action | Competitive H1 receptor inhibitor. Mast cell stabilizer. | ||||||||
| Usage | Indicated for the treatment of itching associated with allergic conjunctivitis. | ||||||||
Contact lenses may be inserted 10 minutes after administration.
| Contraindications |
Hypersensitivity to any component of the product.. |
Pediatric use |
Safety and efficacy not established for patients under 2 years of age. |
Pregnancy |
Skeletal anomalies produced in rats at 5400x human dosage but not at 3300x. |
Rat maternal lethality observed at 540x the normal human ophthalmic dose.
| BAK .005% |
|